Search

Your search keyword '"Kang, Mafei"' showing total 20 results
Start Over Author "Kang, Mafei"
20 results on '"Kang, Mafei"'

2. Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial

Author

Cheng, Ying, Fan, Yun, Zhao, Yanqiu, Huang, Dingzhi, Li, Xingya, Zhang, Peng, Kang, Mafei, Yang, Nong, Zhong, Diansheng, Wang, Zhen, Yu, Yan, Zhang, Yu, Zhao, Jun, Qin, Tai, Chen, Chenqi, Leaw, Shiangjiin, Zheng, Wenjuan, and Song, Yong

Published
2024
Full Text
View/download PDF

3. Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study

Author

Kang Mafei, Xue Feng, Xu Shengyuan, Shi Jieqiong, and Mo Yunyan

Subjects
hepatocellular carcinoma (hcc), anlotinib, s-1, molecule targeted therapy, chemotherapy, Medical physics. Medical radiology. Nuclear medicine, R895-920
Abstract

The aim of the study was to observe the safety and efficacy of anlotinib (ANL) alone or combined with S-1 in the first-line treatment of advanced hepatocellular carcinoma (HCC).

Published
2023
Full Text
View/download PDF

9. sj-docx-1-tam-10.1177_17588359221122715 – Supplemental material for A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer

Author

Yan, Min, Yuan, Peng, Ouyang, Quchang, Cheng, Ying, Han, Guohui, Wang, Dewei, Ran, Li, Sun, Tao, Zhao, Da, Bai, Yuju, Yang, Shun’e, Wang, Xiaojia, Wu, Rong, Zeng, Xiaohua, Yao, Herui, Ji, Xuening, Jiang, Jun, Hu, Xiaohua, Lin, Haifeng, Zheng, Liping, Zhu, Zhitu, Ge, Wei, Yang, Junlan, Cui, Tongjian, Zhang, Xiaozhi, Lu, Fangyang, Li, Wenhui, Xu, Hongyan, Kang, Mafei, Gong, Ping, Zou, Liqun, Liu, Jiang, Zhang, Hongliang, Yu, Hao, and Xu, Binghe

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tam-10.1177_17588359221122715 for A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer by Min Yan, Peng Yuan, Quchang Ouyang, Ying Cheng, Guohui Han, Dewei Wang, Li Ran, Tao Sun, Da Zhao, Yuju Bai, Shun’e Yang, Xiaojia Wang, Rong Wu, Xiaohua Zeng, Herui Yao, Xuening Ji, Jun Jiang, Xiaohua Hu, Haifeng Lin, Liping Zheng, Zhitu Zhu, Wei Ge, Junlan Yang, Tongjian Cui, Xiaozhi Zhang, Fangyang Lu, Wenhui Li, Hongyan Xu, Mafei Kang, Ping Gong, Liqun Zou, Jiang Liu, Hongliang Zhang, Hao Yu and Binghe Xu in Therapeutic Advances in Medical Oncology

Published
2022
Full Text
View/download PDF

10. A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer

Author

Yan, Min, primary, Yuan, Peng, additional, Ouyang, Quchang, additional, Cheng, Ying, additional, Han, Guohui, additional, Wang, Dewei, additional, Ran, Li, additional, Sun, Tao, additional, Zhao, Da, additional, Bai, Yuju, additional, Yang, Shun’e, additional, Wang, Xiaojia, additional, Wu, Rong, additional, Zeng, Xiaohua, additional, Yao, Herui, additional, Ji, Xuening, additional, Jiang, Jun, additional, Hu, Xiaohua, additional, Lin, Haifeng, additional, Zheng, Liping, additional, Zhu, Zhitu, additional, Ge, Wei, additional, Yang, Junlan, additional, Cui, Tongjian, additional, Zhang, Xiaozhi, additional, Lu, Fangyang, additional, Li, Wenhui, additional, Xu, Hongyan, additional, Kang, Mafei, additional, Gong, Ping, additional, Zou, Liqun, additional, Liu, Jiang, additional, Zhang, Hongliang, additional, Yu, Hao, additional, and Xu, Binghe, additional

Published
2022
Full Text
View/download PDF

12. Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial

Author

Shi, Yuankai, primary, Lei, Kaijian, additional, Jia, Yuming, additional, Ni, Bingqiang, additional, He, Zhiyong, additional, Bi, Minghong, additional, Wang, Xicheng, additional, Shi, Jianhua, additional, Zhou, Ming, additional, Sun, Qian, additional, Wang, Guolei, additional, Chen, Dongji, additional, Shu, Yongqian, additional, Liu, Lianke, additional, Guo, Zhongliang, additional, Liu, Yong, additional, Yang, Junquan, additional, Wang, Ke, additional, Xiao, Ke, additional, Wu, Lin, additional, Yi, Tienan, additional, Sun, Debin, additional, Kang, Mafei, additional, Ma, Tianjiang, additional, Mao, Yimin, additional, Shi, Jinsheng, additional, Tang, Tiegang, additional, Wang, Yan, additional, Xing, Puyuan, additional, Lv, Dongqing, additional, Liao, Wangjun, additional, Luo, Zhiguo, additional, Wang, Bin, additional, Wu, Xiaohong, additional, Zhu, Xiaoli, additional, Han, Shuhua, additional, Guo, Qisen, additional, Liu, Rongyu, additional, Lu, Zhiwei, additional, Zhang, Jianyong, additional, Fang, Jian, additional, Hu, Changlu, additional, Ji, Yinghua, additional, Liu, Guolong, additional, Lu, Hong, additional, Wu, Dedong, additional, Zhang, Junhong, additional, Zhu, Shuyang, additional, Liu, Zheng, additional, Qiu, Wensheng, additional, Ye, Feng, additional, Yu, Yan, additional, Zhao, Yanqiu, additional, Zheng, Qinhong, additional, Chen, Jun, additional, Pan, Zhanyu, additional, Zhang, Yiping, additional, Lian, Wenjuan, additional, Jiang, Bo, additional, Qiu, Bo, additional, Zhang, Guojun, additional, Zhang, Hua, additional, Chen, Yanju, additional, Chen, Yuan, additional, Duan, Hongbing, additional, Li, Manxiang, additional, Liu, Shengming, additional, Ma, Lijun, additional, Pan, Hongming, additional, Yuan, Xia, additional, Yuan, Xueli, additional, Zheng, Yulong, additional, Gao, Emei, additional, Zhao, Li, additional, Wang, Shumin, additional, and Wu, Can, additional

Published
2021
Full Text
View/download PDF

13. Sox12 Is a Cancer Stem-Like Cell Marker in Hepatocellular Carcinoma

Author

Zou, Song, Wang, Chen, Liu, Jiansheng, Wang, Qun, Zhang, Dongdong, Zhu, Shengnan, Xu, Shengyuan, Kang, Mafei, and He, Shaozhong

Subjects
Sox12, Carcinoma, Hepatocellular, cancer stem cells (CSCs), Liver Neoplasms, Mice, Nude, Hep G2 Cells, digestive system diseases, Article, SOXC Transcription Factors, hepatocellular carcinoma (HCC), Mice, Drug Resistance, Neoplasm, Cell Line, Tumor, Spheroids, Cellular, Neoplastic Stem Cells, Animals, Humans, Cisplatin, neoplasms, Neoplasm Transplantation
Abstract

Recent studies on molecular carcinogenesis suggest that the chemo-resistance of some cancers is largely due to presence of cancer stem cells (CSCs), which affect the chemotherapy outcome for hepatocellular carcinoma (HCC). However, currently no consensus on a CSC phenotype in HCC has been obtained. Here, we examined Sox12 as a novel CSC marker in HCC. Sox12+ versus Sox12- cells were purified from HCC cell lines. The Sox12+ cells were compared with Sox12- HCC cells for tumor sphere formation, chemo-resistance, tumor formation after serial adoptive transplantations in nude mice, and the frequency of developing distal metastasis. We found that compared to Sox12- HCC cells, Sox12+ HCC cells generated significantly more tumor spheres in culture, were more chemo-resistant to cisplatin, were detected in circulation more frequently, and formed distal tumor more frequently. Moreover, Sox12 appeared to functionally contribute to the stemness of HCC cells. Thus, we conclude that Sox12 may be a novel marker for enriching CSCs in HCC.

Published
2017

16. Overexpression of STAT3/pSTAT3 was associated with poor prognosis in gastric cancer: a meta-analysis

Author

He, Shaozhong, Liao, Guixiang, Liu, Yungen, Huang, Liling, Kang, Mafei, and Chen, Longhua

Subjects
Original Article
Abstract

Signal transducer and activator of transcription 3 (STAT3) and phospho-STAT3 (pSTAT3) play important roles in the development of gastric cancer. STAT3 is often associated with cell survival, proliferation, and transformation. The prognostic value of STAT3/pSTAT3 in patients with gastric cancer remains controversial in numerous published studies. The aim of this study was to summarize recent findings relevant to the prognostic role of STAT3 and pSTAT3 in patients with gastric cancer. A meta-analysis was performed by searching Web of Knowledge, EMBASE, and PubMed to identify studies on the prognostic impact of STAT3/pSTAT3 in gastric cancers in August 2014. In all, 10 studies were included in the analysis. Data were collected for comparing survival rates in patients with high STAT3 levels compared to those with low levels. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. Sensitivity analysis was conducted, and publication bias was evaluated. Eventually, 1667 cases of gastric cancer were subjected to the final analysis. Among patients with gastric cancer, poor survival was predicted by higher expressions of STAT3 (HR=2.30; 95% CI=1.13-4.68; P=0.02) and pSTAT3 (HR=1.75; 95% CI=1.17-2.61; P=0.006). Moreover, overexpression of STAT3 was associated with poor tumor stage. Additionally, our analysis did not show any statistically significant effect of publication bias regarding STAT3 or pSTAT3. The results of this meta-analysis demonstrated that overexpression of STAT3 and pSTAT3 was associated with poor prognosis in gastric cancer.

Published
2015

19. Overexpression of STAT3/pSTAT3 was associated with poor prognosis in gastric cancer: a meta-analysis.

Author

He S, Liao G, Liu Y, Huang L, Kang M, and Chen L

Abstract

Signal transducer and activator of transcription 3 (STAT3) and phospho-STAT3 (pSTAT3) play important roles in the development of gastric cancer. STAT3 is often associated with cell survival, proliferation, and transformation. The prognostic value of STAT3/pSTAT3 in patients with gastric cancer remains controversial in numerous published studies. The aim of this study was to summarize recent findings relevant to the prognostic role of STAT3 and pSTAT3 in patients with gastric cancer. A meta-analysis was performed by searching Web of Knowledge, EMBASE, and PubMed to identify studies on the prognostic impact of STAT3/pSTAT3 in gastric cancers in August 2014. In all, 10 studies were included in the analysis. Data were collected for comparing survival rates in patients with high STAT3 levels compared to those with low levels. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. Sensitivity analysis was conducted, and publication bias was evaluated. Eventually, 1667 cases of gastric cancer were subjected to the final analysis. Among patients with gastric cancer, poor survival was predicted by higher expressions of STAT3 (HR=2.30; 95% CI=1.13-4.68; P=0.02) and pSTAT3 (HR=1.75; 95% CI=1.17-2.61; P=0.006). Moreover, overexpression of STAT3 was associated with poor tumor stage. Additionally, our analysis did not show any statistically significant effect of publication bias regarding STAT3 or pSTAT3. The results of this meta-analysis demonstrated that overexpression of STAT3 and pSTAT3 was associated with poor prognosis in gastric cancer.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results